COMPARISON OF EFFICACY AND SIDE EFFECTS OF SECONDLINE DASATINIB AND NILOTINIB THERAPIES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB: PB1947
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI